Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.37 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL346463 | 0.71 | CYP2D6 (0.39) | — | |
| SCHEMBL3410221 | 0.71 | HDAC2 (0.41) | CYP11B1CYP11B2HDAC2 | |
| SCHEMBL3244130 | 0.69 | POLB (0.51) | — | |
| SCHEMBL898966 | 0.69 | CA12 (0.62) | CA12CA7CA14 | |
| SCHEMBL16207447 | 0.69 | CA12 (0.62) | CA12CA7CA14 | |
| SCHEMBL4110022 | 0.69 | NAMPT (0.39) | NAMPTCYP11B1CYP11B2CA12CA7 | |
| SCHEMBL18653947 | 0.69 | CYP11B1 (0.37) | CYP11B1CYP11B2HDAC2 | |
| SCHEMBL20417946 | 0.69 | CYP11B1 (0.37) | CYP11B1CYP11B2HDAC2 | |
| SCHEMBL357308 | 0.69 | CYP11B1 (0.37) | CYP11B1CYP11B2HDAC2 | |
| SCHEMBL357309 | 0.69 | CYP11B1 (0.37) | CYP11B1CYP11B2HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8183380-B2 | 2-aminoquinolines | HOFFMANN-LA ROCHE INC. (US) | 2012-05-22 | — | — | US | claimed |
| US-20090227570-A1 | 2-AMINOQUINOLINES | HOFFMANN-LA ROCHE, INC. | 2009-09-10 | — | — | US | claimed |
| US-8183380-B2 | 2-aminoquinolines | HOFFMANN-LA ROCHE INC. (US) | 2012-05-22 | — | — | US | disclosed |
| EP-2262789-A1 | 2-AMINOQUINOLINES | F. Hoffmann-La Roche AG (CH) | 2010-12-22 | — | — | EP | disclosed |
| WO-2009109477-A1 | 2-AMINOQUINOLINES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-09-11 | — | — | WO | disclosed |
| US-20090227570-A1 | 2-AMINOQUINOLINES | HOFFMANN-LA ROCHE, INC. | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227570-A1 | 2-AMINOQUINOLINES | HTR5A, HTR2C, HTR2A | NAMPT 2203/4885CYP11B1 2157/4885CYP11B2 1422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.